PCSK9抑制剂与非黑色素瘤皮肤癌风险的回顾性队列研究
本研究基于TriNetX美国协作网络数据库,纳入2016至2022年间接受他汀治疗的≥40岁动脉粥样硬化性心血管疾病(ASCVD)成人,采用目标试验设计与倾向评分匹配,比较加用PCSK9抑制剂与继续他汀治疗的非黑色素瘤皮肤癌(NMSC)风险。结果显示PCSK9抑制剂组NMSC、基底细胞癌(BCC)和皮肤鳞状细胞癌(cSCC)风险均降低。
要点
- ASCVD他汀治疗患者加用PCSK9抑制剂与NMSC风险降低相关(HR 0.78)。
- BCC和cSCC风险亦降低,HR分别为0.78和0.79。
- 依洛尤单抗和阿利西尤单抗亚组分析均显示NMSC风险降低。
核心结论
- 服用PCSK9抑制剂的ASCVD患者发生NMSC的风险低于未服用者。
研究设计与样本
- 回顾性队列研究,分析TriNetX美国协作网络数据库2016至2022年数据。
- 纳入≥40岁接受他汀治疗的ASCVD成人,采用目标试验设计和倾向评分匹配比较组间风险。
主要发现
- 共分析73 636例ASCVD患者,PCSK9抑制剂组NMSC风险HR 0.78(95%CI 0.71-0.87)。
- BCC风险HR 0.78(95%CI 0.69-0.89),cSCC风险HR 0.79(95%CI 0.67-0.93)。
- 依洛尤单抗和阿利西尤单抗亚组分析均显示NMSC风险降低。
- 分层分析显示65-79岁、80岁以上及男性患者结果相似。
临床怎么用
- 临床中对于ASCVD他汀治疗患者,加用PCSK9抑制剂可能有助于降低NMSC风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Growing evidence has shown that cholesterol metabolism abnormalities involve carcinogenesis. Proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors have been reported to inhibit tumour progression and prevent ultraviolet-related skin damage. OBJECTIVES: To investigate the association of PCSK9 inhibitors with the risk of nonmelanoma skin cancer (NMSC). METHODS: This retrospective cohort study analysed data from the US Collaborative Network in the TriNetX database. Adults aged ≥ 40 years with atherosclerotic cardiovascular disease (ASCVD) under statin therapy between 2016 and 2022 were identified. A target trial design was used to compare the risk of NMSC, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), in patients also treated with PCSK9 inhibitors or continuing statin treatment (the control group). Each head-to-head comparison involved propensity score matching. Hazard ratios (HRs) were estimated using Cox proportional hazard models. Stratified analyses based on age, sex, Fitzpatrick skin type and immune status were also performed. RESULTS: A total of 73 636 patients with ASCVD were analysed. Compared with the control group, patients with ASCVD initiating PCSK9 inhibitors had lower risks of developing NMSC [HR 0.78, 95% confidence interval (CI) 0.71-0.87], BCC (HR 0.78, 95% CI 0.69-0.89) and cSCC (HR 0.79, 95% CI 0.67-0.93). Subanalyses revealed a reduced risk of NMSC with each PCSK9 inhibitor, namely evolocumab and alirocumab. Stratified analyses showed similar results in patients aged 65-79 years, those older than 80 years and in men. CONCLUSIONS: Our study indicated that patients with ASCVD taking PCSK9 inhibitors have a lower risk of incident NMSC than those not taking PCSK9 inhibitors. Abnormalities in the body’s metabolism of a type of fat called cholesterol can lead to the development of skin cancer. Certain drugs that lower the levels of fats (‘lipids’) in the body may reduce the risk of a person developing a type of skin cancer called non-melanoma skin cancer (or ‘NMSC’ for short). These drugs include a type of medication called ‘PCSK9 inhibitors’. It is not known if giving PCSK9 inhibitors to patients already taking a type of drug called a ‘statin’ to lower their cholesterol has a beneficial effect in reducing their risk of developing NMSC. We investigated the association of PCSK9 inhibitors with NMSC. We did this using data from the USA. We compared the risk of developing NMSC in adults with heart disease taking PCSK9 inhibitors plus a statin with people who were only taking statins. A total of 73,236 people were included. We found that patients who took PCSK9 inhibitors as well as a statin had less risk of developing NMSC than people who only took a statin. Our findings suggest that using PCSK9 inhibitors decreases the risk of a person developing NMSC. The preventive role of PCSK9 inhibitors is worth considering in clinical practice.
引用
- Li CY, Wang WT, Ma SH, et al. Association of proprotein convertase subtilisin/kexin type-9 inhibitors with risk of nonmelanoma skin cancer: a retrospective cohort study. Br J Dermatol. 2025. PMID: 39585798. doi:10.1093/bjd/ljae438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。